This is a human monochlonal antibody that is not likely to cause allergic reactions or tolerance as would Infliximab and is used as sub-cutaneous injection once every 2 weeks at a dose of 20-40mg. It can be uncomfortable and it is as effective as the 8 weekly infusions of Infliximab are. Both Infliximab and Adalimumab can be used for ulcerative colitis and Crohn’s disease but NICE guidance is present only for Crohn’s disease in children.